Overview

* BioMarin Q2 2025 revenue rises 16% yr/yr, beating analyst expectations

* Non-GAAP diluted EPS for Q2 beats estimates, rising 50% yr/yr

* Co completes acquisition of Inozyme, adding BMN 401 to enzyme therapies

Outlook

* BioMarin raises full-year 2025 revenue guidance to $3.125 bln-$3.200 bln

* Company expects 2025 Non-GAAP EPS of $4.40 to $4.55

* BioMarin sees 2025 Non-GAAP operating margin at 33%-34%

* Company anticipates limited impact from new tariffs in 2025

Result Drivers

* VOXZOGO DEMAND - 20% revenue growth driven by strong global demand and new patient initiations

* ENZYME THERAPIES - 15% revenue increase due to patient demand and large government orders

* GENERIC COMPETITION - Decline in KUVAN revenues attributed to loss of market exclusivity

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Beat $825 mln $760 mln

Revenue (23

Analysts

)

Q2 Beat $1.44 $0.83

Adjusted (17

EPS Analysts

)

Q2 EPS $1.23

Q2 Net $241 mln

Income

Q2 Basic $1.25

EPS

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 23 "strong buy" or "buy", 6 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the pharmaceuticals peer group is "buy"

* Wall Street's median 12-month price target for BioMarin Pharmaceutical Inc ( BMRN ) is $95.00, about 38.8% above its August 1 closing price of $58.14

* The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 18 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)